Beacon Investment Advisory Services Inc. Has $22.24 Million Stake in Zoetis Inc. $ZTS

Key Points

• Beacon Investment Advisory Services Inc. reduced its stake in Zoetis Inc. by 11.2% during the 2nd quarter, now holding 142,613 shares valued at approximately $22.24 million.
• Zoetis reported quarterly earnings of $1.76 per share, surpassing expectations, with revenues of $2.46 billion, up 4.2% year-over-year.
• Analysts have mixed ratings on Zoetis, with a consensus price target of $200.88, reflecting ongoing interest despite some downgrades from firms like Leerink Partners.

Beacon Investment Advisory Services Inc. decreased its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 11.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 142,613 shares of the company's stock after selling 17,911 shares during the quarter. Beacon Investment Advisory Services Inc.'s holdings in Zoetis were worth $22,241,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Nova Wealth Management Inc. acquired a new stake in shares of Zoetis during the first quarter worth about $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis during the first quarter worth about $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis during the first quarter worth about $29,000. Cornerstone Planning Group LLC raised its position in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after purchasing an additional 88 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after purchasing an additional 120 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Down 0.7%

Shares of Zoetis stock opened at $141.65 on Thursday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The business's 50 day simple moving average is $150.63 and its 200 day simple moving average is $156.07. The firm has a market cap of $62.78 billion, a PE ratio of 24.38, a P/E/G ratio of 2.29 and a beta of 0.89. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $197.51.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business's revenue was up 4.2% compared to the same quarter last year. During the same period last year, the company earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ZTS. Piper Sandler raised their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and dropped their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Argus reissued a "buy" rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.